Scientists believe an anti-viral nasal spray could treat Covid-19 and stop the infection reaching the lungs, following positive lab tests in Britain.
University of St Andrews spin-out company Pneumagen has carried out three separate lab-based studies into preventing coronavirus infections, including Sars-CoV-2 infection, the cause of Covid-19.
These have used Neumifil and multivalent Carbohydrate Binding Modules (mCBMs), generated using its GlycoTarge technology. Neumifil, the company's lead mCBM, is already being developed for the universal treatment of respiratory tract infections (RTIs), including Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), and now coronaviruses.